Gilead’s Inhalable Form Of Remdesivir
Gilead starts early-stage testing of an inhalable form of remdesivir.
Coronavirus Drug that can be Inhaled: The American biopharmaceutical company, Gilead Sciences Inc starts early-stage testing of inhalable remdesivir, the coronavirus drug.
In early May 2020, in order to treat severe COVID-19 patients who are hospitalized, emergency use authorization was given to the drug Remdesivir in the United States.
On Wednesday, Gilead Sciences said that for the use of Remdesivir outside of hospitals, the firm has started an early-stage study of its antiviral Covid-19 treatment remdesivir that can be inhaled. In this trial, the company said that the drug will be tested particularly in those cases where the disease has not progressed to require hospitalization and will enroll about 60 healthy Americans aged between 18 and 45.
Currently, the drug is used intravenously. Through a nebulizer, an inhaled formulation would be given, which could potentially allow for easier administration outside hospitals. In order to treat severe COVID-19 patients who are hospitalized, emergency use authorization was given to the drug Remdesivir in the United States.
By delivering the drug directly to the primary site of infection, Gilead is hoping to target the disease at the onset with the inhaled form of remdesivir. Since the drug helped shorten hospital recovery times in a clinical trial, remdesivir is believed to be at the forefront in the fight against the coronavirus.
In order to evaluate remdesivir when used in combination with anti-inflammatory medicines, Gilead also plans to start additional clinical trials.
A research-based biopharmaceutical company, Gilead Sciences, Inc, headquartered in Foster City, California focuses on the discovery, development, and commercialization of innovative medicines. In response to the novel coronavirus, COVID-19 outbreak, Gilead is working closely with global health authorities through the appropriate use of the investigational drug remdesivir, the drug shown beneficial in fighting COVID-19 infection.
Gilead’s Inhalable Form Of Remdesivir – Gilead starts early-stage testing of an inhalable form of remdesivir